CN109675050A - 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 - Google Patents
以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 Download PDFInfo
- Publication number
- CN109675050A CN109675050A CN201811608721.5A CN201811608721A CN109675050A CN 109675050 A CN109675050 A CN 109675050A CN 201811608721 A CN201811608721 A CN 201811608721A CN 109675050 A CN109675050 A CN 109675050A
- Authority
- CN
- China
- Prior art keywords
- acid
- camptothecine
- analog
- parent nucleus
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811608721.5A CN109675050A (zh) | 2018-12-27 | 2018-12-27 | 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811608721.5A CN109675050A (zh) | 2018-12-27 | 2018-12-27 | 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109675050A true CN109675050A (zh) | 2019-04-26 |
Family
ID=66189955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811608721.5A Pending CN109675050A (zh) | 2018-12-27 | 2018-12-27 | 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109675050A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115403483A (zh) * | 2021-07-02 | 2022-11-29 | 河南省儿童医院郑州儿童医院 | 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用 |
WO2023151513A1 (en) * | 2022-02-08 | 2023-08-17 | Canwell Biotech Limited | Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100240602A1 (en) * | 2001-03-20 | 2010-09-23 | Burke Thomas G | Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
CN104163823A (zh) * | 2014-04-30 | 2014-11-26 | 浙江工业大学 | 一种喜树碱与青蒿琥酯偶联物及其制备方法与应用 |
CN106588945A (zh) * | 2016-11-16 | 2017-04-26 | 浙江大学 | 阿司匹林抗癌药物偶联物、合成方法及其应用 |
-
2018
- 2018-12-27 CN CN201811608721.5A patent/CN109675050A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100240602A1 (en) * | 2001-03-20 | 2010-09-23 | Burke Thomas G | Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
CN104163823A (zh) * | 2014-04-30 | 2014-11-26 | 浙江工业大学 | 一种喜树碱与青蒿琥酯偶联物及其制备方法与应用 |
CN106588945A (zh) * | 2016-11-16 | 2017-04-26 | 浙江大学 | 阿司匹林抗癌药物偶联物、合成方法及其应用 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115403483A (zh) * | 2021-07-02 | 2022-11-29 | 河南省儿童医院郑州儿童医院 | 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用 |
CN115403483B (zh) * | 2021-07-02 | 2024-01-26 | 河南省儿童医院郑州儿童医院 | 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用 |
WO2023151513A1 (en) * | 2022-02-08 | 2023-08-17 | Canwell Biotech Limited | Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ding et al. | Discovery and development of natural product oridonin-inspired anticancer agents | |
Smith et al. | Cocrystals of quercetin with improved solubility and oral bioavailability | |
Zhao et al. | Design, synthesis and biological evaluation of brain targeting l-ascorbic acid prodrugs of ibuprofen with “lock-in” function | |
CN110981870B (zh) | 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途 | |
Cen et al. | Development of tacrine-bifendate conjugates with improved cholinesterase inhibitory and pro-cognitive efficacy and reduced hepatotoxicity | |
Yang et al. | Theoretical calculation and structural analysis of the cocrystals of three flavonols with praziquantel | |
Zhang et al. | Cocrystals of natural products: Improving the dissolution performance of flavonoids using betaine | |
KR101990214B1 (ko) | 표적 특이적 항암 약물전구체 | |
CN109575099A (zh) | 达玛烷皂苷元衍生物及其制备方法和应用 | |
Schwikkard et al. | The antiangiogenic activity of naturally occurring and synthetic homoisoflavonoids from the Hyacinthaceae (sensu APGII) | |
Zhou et al. | Structure determination and in vitro/vivo study on carbamazepine-naringenin (1: 1) cocrystal | |
CN109675050A (zh) | 以喜树碱为母核的类似物与非甾体抗炎药物的偶联物及其制备与应用 | |
CN104513290B (zh) | 雷醇内酯衍生物及其应用 | |
Yu et al. | Supramolecular self-assembly and perfected in vitro/vivo property of 5-fluorouracil and ferulic acid on the strength of double optimized strategy: the first 5-fluorouracial-phenolic acid nutraceutical cocrystal with synergistic antitumor efficacy | |
Chang-Can et al. | Development of liquiritigenin-phospholipid complex with the enhanced oral bioavailability | |
CN103222970A (zh) | 不对称单羰基姜黄素类似物在制备抗肿瘤药物中的应用 | |
Wang et al. | Diclofenac and eugenol hybrid with enhanced anti-inflammatory activity through activating HO-1 and inhibiting NF-κB pathway in vitro and in vivo | |
CN102898433A (zh) | 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途 | |
Mohapatra et al. | Coamorphisation of acetyl salicylic acid and curcumin for enhancing dissolution, anti-inflammatory effect and minimizing gastro toxicity | |
CN106317033B (zh) | 一种水飞蓟宾23-取代衍生物及其注射剂的制备方法和用途 | |
WO2011131102A1 (zh) | 含笑内酯的制备方法及其用途 | |
Kang et al. | Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia | |
CN109232703A (zh) | 含16-(1′-芳香基-1′,2′,3′-三氮唑)亚甲基-雄甾-17-酮衍生物 | |
CN107056739B (zh) | Bola型槲皮素衍生物及其制备方法和应用 | |
CN115124531A (zh) | 一类4-氮杂色胺酮芳香硫醚衍生物、制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Qingyong Inventor after: Wang Mengke Inventor after: Wang Wenchao Inventor after: Xia Lihua Inventor after: Zhou Leilei Inventor after: Weng Qi Inventor after: Yu Endian Inventor after: Yue Hanlin Inventor before: Li Qingyong Inventor before: Wang Mengke Inventor before: Xia Lihua Inventor before: Wang Wenchao Inventor before: Zhou Leilei Inventor before: Weng Qi Inventor before: Yu Endian Inventor before: Yue Hanlin |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190426 |